Transforming Growth Factor Beta 2 - Pipeline Review, H1 2020

Published: January 2020
Pages: 66
Code: B207E904BB42D2DE8E5AA9875ACEDC62
Format: PDF
Publisher Global Markets Direct
From Add to basket
$ 3,500.00
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report , outlays comprehensive information on the Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Transforming growth factor beta 2 (TGF-β2) is a polypeptide member of the transforming growth factor beta superfamily of cytokines encoded by the TGFB2 gene. It regulates proliferation, differentiation, adhesion and migration. It has suppressive effects on interleukin-2 dependent T-cell growth. The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 4 and 2 respectively.
Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Ophthalmology, Gastrointestinal, Dermatology, Genetic Disorders, Genito Urinary System And Sex Hormones, Metabolic Disorders, Musculoskeletal Disorders and Respiratory which include indications Glioblastoma Multiforme (GBM), Open-Angle Glaucoma, Age Related Macular Degeneration, Choroidal Neovascularization, Colorectal Cancer, Diabetic Macular Edema, Fibrosis, Head And Neck Cancer, High-Grade Glioma, Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis, Melanoma, Metastatic Breast Cancer, Metastatic Lung Cancer, Myelodysplastic Syndrome, Non-Alcoholic Steatohepatitis (NASH), Non-Small Cell Lung Cancer, Osteogenesis Imperfecta, Pancreatic Cancer, Pediatric Diffuse Intrinsic Pontine Glioma, Proliferative Vitreoretinopathy (PVR), Scar and Solid Tumor.
Furthermore, this report also reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Additonal Information

  • - The report provides a snapshot of the global therapeutic landscape for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2)
  • - The report reviews Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • - The report reviews key players involved in Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics and enlists all their major and minor projects
  • - The report assesses Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • - The report summarizes all the dormant and discontinued pipeline projects
  • - The report reviews latest news and deals related to Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) targeted therapeutics

Companies Mentioned

Avacta Life Sciences Ltd
Genzyme Corp
Isarna Therapeutics GmbH
Novartis AG
Oncotelic Inc
RadBio

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage Identify and understand the targeted therapy areas and indications for Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) Identify the use of drugs for target identification and drug repurposing Identify potential new clients or partners in the target demographic Develop strategic initiatives by understanding the focus areas of leading companies Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics Devise corrective measures for pipeline projects by understanding Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) development landscape Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Add to basket
  • Table of Contents
  • List of Tables
  • List of Figures
  • Introduction
  • Global Markets Direct Report Coverage
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Overview
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Companies Involved in Therapeutics Development
  • Avacta Life Sciences Ltd
  • Genzyme Corp
  • Isarna Therapeutics GmbH
  • Novartis AG
  • Oncotelic Inc
  • RadBio
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Drug Profiles
  • Antisense Oligonucleotide 1 to Inhibit TGFB2 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • AVA-027 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Dormant Products
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Discontinued Products
  • Transforming Growth Factor Beta 2 (BSC1 Cell Growth Inhibitor or Cetermin or Glioblastoma Derived T Cell Suppressor Factor or Polyergin or TGFB2) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 02, 2019: Mateon Therapeutics team publishes three new peer-reviewed oncology articles outlining the clinical impact Potential of its first-in-class anti-TGF-beta RNA therapeutic OT101/Trabedersen
  • Nov 18, 2019: Mateon Therapeutics to present new and updated data for OT101 (Trabedersen) activity against brain tumors at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting
  • Oct 23, 2019: New research study provides target validation for Mateon's first-in-class RNA therapeutic OT101 for the treatment of difficult to treat forms of childhood brain tumor
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
  • List of Tables
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indications, H1 2020
  • Number of Products under Development by Indications, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Investigation by Universities/Institutes, H1 2020
  • Products under Investigation by Universities/Institutes, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Avacta Life Sciences Ltd, H1 2020
  • Pipeline by Genzyme Corp, H1 2020
  • Pipeline by Isarna Therapeutics GmbH, H1 2020
  • Pipeline by Novartis AG, H1 2020
  • Pipeline by Oncotelic Inc, H1 2020
  • Pipeline by RadBio, H1 2020
  • Dormant Projects, H1 2020
  • Discontinued Products, H1 2020
  • List of Figures
  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020

Keywords
;